Company intelligence / Profile preview
Rhythm Biotherapeutics
Ottawa, Ontario, Canadarthm.bio ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Preclinical
01
Overview
Rhythm Biotherapeutics is developing a novel, preclinical-stage exosome-based therapy aimed at preventing and curing atrial fibrillation by addressing the underlying physiological causes rather than just managing symptoms. Preclinical evidence suggests their human cardiac exosome approach may prevent inflammation and fibrosis associated with AF, with several peer-reviewed publications supporting efficacy in animal models[1][4].
- Therapeutic areas
- Cardiovascular
- Modalities
- Exosome therapy (human cardiac exosomes)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Rhythm Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rhythm Biotherapeutics.